Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

If you have obesity, losing even a little weight helps not only improve your overall health, but also prevent liver issues ...

These organizations can help you educate yourself, spread awareness, and connect with the MASH community to help you better ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Metabolic dysfunction-associated steatohepatitis (MASH) is often referred to as a “silent disease,” as it typically shows no signs of symptoms in early stages. But it can come with certain ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly to develop treatments for cardiovascular and ...

OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...